First PMDA-approved molecular residual disease (MRD) test in Japan, supporting the use of Signatera in the adjuvant setting Commercial launch ex...
First regulatory approval for iza-bren (BL-B01D1), a first-in-class EGFR×HER3 bispecific antibody-drug conjugate (ADC) Represents an important n...
Wayrilz is a BTK inhibitor that works through multi-immune modulation to help address the underlying causes of immune thrombocytopenia (ITP) Approval ...
First-in-human Phase 1 study in 56 healthy participants demonstrated KIT2014’s safety and tolerability KIT2014 is being developed as an inhalati...
Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO) for biotechs, announced a significant expansion of its Asia Pac...
Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma Approval based on multiple studies, including th...
Move reinforces Axplora’s integrated API supply model, expands critical manufacturing capabilities in India and enables Farmabios to sharpen ...
Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on autoimmune and inflammatory dise...
First partnership announced under Verge Labs' platform-first model; Tenacia will apply Verge's AI platform and proprietary multimodal...
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics...
As drug development becomes increasingly complex, early-phase clinical trials are taking on a far more strategic role than simply establish...
Global pharmaceutical leader Lupin Limited announced that the United States Food and Drug Administration (U.S. FDA) has approved its ranibizum...
Orphan Drug Designation (ODD) recognizes Duchenne muscular dystrophy as a rare disease with significant unmet medical need without an established treat...
As healthcare systems around the world grapple with rising costs, growing chronic disease burdens, and increasing demand for innovative therapies, biosimil...
© 2026 Biopharma Boardroom. All Rights Reserved.
